Eccles SA - Search Results

1

The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.

Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD. Walton MI, et al. Among authors: eccles sa. Mol Cancer Ther. 2010 Jan;9(1):89-100. doi: 10.1158/1535-7163.MCT-09-0938. Epub 2010 Jan 6. Mol Cancer Ther. 2010. PMID: 20053762 Free article.

2

Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.

Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Modjtahedi H, et al. Br J Cancer. 1993 Feb;67(2):254-61. doi: 10.1038/bjc.1993.49. Br J Cancer. 1993. PMID: 7679281 Free PMC article.

3

Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Modjtahedi H, Eccles S, Sandle J, Box G, Titley J, Dean C. Modjtahedi H, et al. Cancer Res. 1994 Apr 1;54(7):1695-701. Cancer Res. 1994. PMID: 8137284

4

Immunotherapy with antibodies to the EGF receptor.

Dean C, Modjtahedi H, Eccles S, Box G, Styles J. Dean C, et al. Int J Cancer Suppl. 1994;8:103-7. doi: 10.1002/ijc.2910570722. Int J Cancer Suppl. 1994. PMID: 8194887

5

Phosphocholine and choline content of rat sarcoma cells grown in the presence and absence of serum.

Smith TA, Eccles S, Box G, Titley JC, Leach MO, McCready VR. Smith TA, et al. Anticancer Res. 1996 May-Jun;16(3B):1389-92. Anticancer Res. 1996. PMID: 8694506

6

In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance.

Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Charlton P, Templeton D, Bevan PB. Mistry P, et al. Br J Cancer. 1999 Apr;79(11-12):1672-8. doi: 10.1038/sj.bjc.6690267. Br J Cancer. 1999. PMID: 10206276 Free PMC article.

7

Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S. O-Charoenrat P, et al. Int J Cancer. 2000 May 1;86(3):307-17. doi: 10.1002/(sici)1097-0215(20000501)86:3<307::aid-ijc2>3.0.co;2-i. Int J Cancer. 2000. PMID: 10760816

8

Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer.

Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, Page MJ. Patel S, et al. Int J Cancer. 2002 Feb 1;97(4):416-24. doi: 10.1002/ijc.1638. Int J Cancer. 2002. PMID: 11802201

9

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S. Modjtahedi H, et al. Int J Cancer. 2003 Jun 10;105(2):273-80. doi: 10.1002/ijc.11055. Int J Cancer. 2003. PMID: 12673691

10

Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo.

Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S. Spruce BA, et al. Cancer Res. 2004 Jul 15;64(14):4875-86. doi: 10.1158/0008-5472.CAN-03-3180. Cancer Res. 2004. PMID: 15256458

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

233 results

Search Page

Filters